← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

EGFR Mutant NSCLC

MONDO:0005233 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 33 citations openscientist · 55 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

EGFR-mutant NSCLC is driven by somatic activating (gain-of-function) mutations in the EGFR tyrosine kinase domain — predominantly exon 19 deletions and the exon 21 L858R substitution — which cause constitutive, ligand-independent kinase activation that drives the RAS-MAPK, PI3K-AKT-mTOR, and JAK-STAT3 oncogenic cascades.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factorgene_function
ProviderStanceScoreEvidence
falcon CONCORDANT 96% EGFR-mutant NSCLC is driven by activating mutations in EGFR (most commonly exon 19 deletions and exon 21 L858R), which cause constitutive kinase activation, ligand-independent dimerization, and chronic propagation of key oncogenic cascades including RAS/RAF/MEK/ERK (MAPK), PI3K/AKT/mTOR, and JAK/STAT (notably STAT3)
Falcon states the driver mutations, ligand-independent constitutive activation, and the same three effector cascades directly.
DOI:10.1080/14728222.2023.2218613
openscientist CONCORDANT 95% EGFR-mutant non-small cell lung cancer (NSCLC) is a molecularly defined cancer subtype driven by somatic gain-of-function mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain, predominantly exon 19 deletions (~45%) and the L858R point mutation in exon 21 (~40%)
OpenScientist matches the driver-mutation mechanism and adds the somatic designation and approximate variant frequencies (~45% / ~40%).

EGFR mutations show marked ethnic/geographic enrichment, occurring far more frequently in East Asian than in Western/Caucasian NSCLC patients, and are concentrated in adenocarcinoma and never-smokers; the common exon 19 and L858R variants account for roughly 80-90% of EGFR mutations.

MAJORITY INTEGRATED
epidemiologygenetic_factor
ProviderStanceScoreEvidence
openscientist CONCORDANT 92% East Asian patients have a much higher prevalence of epidermal growth factor receptor (EGFR) mutation (approximately 30% vs. 7%, predominantly among patients with adenocarcinoma and never-smokers)
OpenScientist gives the specific ~30% vs ~7% East Asian/Caucasian contrast and the adenocarcinoma/never-smoker enrichment.
PMID:21527061
falcon PARTIAL 60% EGFR mutations occur in ~10–20% of Western and ~30–50% of Asian patients; exon 19/L858R account for ~80–90% of common EGFR mutations.
Falcon agrees on the Western-vs-Asian enrichment and the ~80-90% exon 19/L858R share, but reports a wider/higher Asian band (~30-50% vs OpenScientist's ~30%) and does not tie the rate to the never-smoker/ adenocarcinoma demographic in this statement — overlapping but not fully concordant on the numbers.

The third-generation, mutant-selective EGFR-TKI osimertinib is the standard first-line therapy for sensitizing EGFR mutations, with subsequent management guided by resistance mechanisms.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Osimertinib is first-line for sensitizing EGFR mutations, with subsequent strategy guided by resistance mechanisms (re-biopsy/NGS).
Falcon names osimertinib as first-line standard of care.
openscientist CONCORDANT 95% established as the current standard of care across multiple disease stages: first-line metastatic (FLAURA), adjuvant resected (ADAURA), and consolidation after chemoradiotherapy for unresectable stage III (LAURA).
OpenScientist confirms osimertinib as standard of care and extends it across the metastatic (FLAURA), adjuvant (ADAURA), and consolidation (LAURA) settings.

Resistance to EGFR-TKIs is essentially inevitable and heterogeneous: on-target EGFR mutations (notably C797S after osimertinib) plus EGFR-independent mechanisms — bypass RTK activation (e.g. MET/HER2 amplification), oncogenic fusions, and lineage/histologic transformation.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factortreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 93% Resistance emerges via on-target tertiary EGFR mutations (e.g., C797S after osimertinib), activation of bypass receptor tyrosine kinases (RTKs; MET and ERBB2/HER2 amplification), downstream pathway alterations, oncogenic fusions, and lineage plasticity
Falcon enumerates on-target C797S plus bypass MET/HER2, fusions, and lineage plasticity as the resistance landscape.
DOI:10.1080/14728222.2023.2218613
openscientist CONCORDANT 92% While EGFR-dependent mechanisms consist mainly of the C797S EGFR mutation, EGFR-independent mechanisms include bypass pathways, oncogenic fusions, and phenotypic transformation, among others.
OpenScientist frames the same on-target (C797S) vs EGFR-independent (bypass, fusion, transformation) dichotomy.
PMID:37060646

EGFR-mutant NSCLC has an immunologically cold, immunosuppressive tumor microenvironment (low tumor mutational burden, impaired antigen presentation, suppressive immune programs), underlying the limited benefit of single-agent PD-1/PD-L1 checkpoint blockade in this genotype.

UNANIMOUS INTEGRATED
pathophysiologytreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% The tumor microenvironment (TME) is characteristically immunosuppressed, with impaired antigen presentation (HLA-I), enrichment of regulatory T cells (Tregs), and myeloid programs that collectively underlie the relatively poor efficacy of PD-1/PD-L1 blockade in this genotype.
Falcon links the immunosuppressed TME (impaired HLA-I, Tregs, myeloid programs) to poor PD-1/PD-L1 response.
openscientist CONCORDANT 85% Limited ICI monotherapy benefit confirmed by meta-analysis of 87 studies
OpenScientist agrees the cold TME (low TMB ~3.3 mut/Mb, sparse CD8+ TILs) yields limited immune-checkpoint-inhibitor monotherapy benefit, confirmed by an 87-study meta-analysis.
PMID:34295687

PD-L1 expression carries adverse significance in EGFR-mutant NSCLC: high PD-L1 (>=50%) paradoxically predicts worse outcomes on osimertinib, and PD-L1 also contributes mechanistically to EGFR-TKI resistance (via induced autophagy).

MAJORITY LEAD
prognosispathophysiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 88% PD-L1 ≥50% was associated with over twofold risk of progression
OpenScientist reports the paradoxical prognostic association — high PD-L1 predicts shorter PFS/OS on osimertinib (HR 3.03).
PMID:41371099
falcon PARTIAL 50% PD-L1 induces autophagy and primary EGFR-TKI resistance through MAPK signaling
Falcon supports a detrimental PD-L1 role but frames it as a resistance mechanism (PD-L1-induced autophagy) rather than the paradoxical prognostic association OpenScientist quantifies — related but not the same claim.

EGFR-mutant NSCLC has a high propensity for CNS/brain metastases, which are a key clinical feature over the disease course and guide therapy selection.

MAJORITY INTEGRATED
phenotype
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% High propensity for brain metastases (25–40%), including leptomeningeal metastases (3–5%)
OpenScientist quantifies brain-metastasis (25-40%) and leptomeningeal (3-5%) burden.
falcon PARTIAL 55% frequent brain metastases during TKI resistance
Falcon notes frequent brain metastases qualitatively but gives no incidence figures — concordant in direction, less quantitative.

The BIM (BCL2L11) germline deletion polymorphism impairs TKI-induced apoptosis and functions as a pharmacogenomic modifier of EGFR-TKI response.

MAJORITY LEAD
genetic_factortreatmentprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% A germline 2903 bp deletion polymorphism of Bcl-2-like protein 11 (BIM) causes reduced expression of proapoptotic BH3-only BIM protein and blocks TKI-induced apoptosis of tumor cells
OpenScientist details the germline BIM deletion, its apoptosis defect, and its pharmacogenomic effect (HR 1.35 for PFS; ~15.8% of Asian patients).
PMID:34722761
falcon PARTIAL 50% apoptosis is counteracted in part by BIM (BCL2L11) loss/polymorphisms
Falcon notes BIM loss/polymorphism impairs TKI-induced apoptosis but does not supply the quantitative pharmacogenomic or population-frequency data.

Osimertinib has superior CNS activity, crossing the blood-brain barrier to achieve greater brain exposure than other EGFR-TKIs and delivering high intracranial response rates.

SINGLE LEAD
treatmentprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Osimertinib penetrates the blood-brain barrier and achieves greater exposure in the brain compared with other EGFR-TKIs
OpenScientist reports osimertinib's BBB penetration and high CNS ORR (70-71%) versus other EGFR-TKIs.
PMID:36652172, PMID:32954743
falcon SILENT —
Falcon's pathophysiology-focused report notes frequent CNS involvement but does not address osimertinib's CNS-specific efficacy or BBB penetration.

Narrative

Overview

Both providers frame EGFR-mutant NSCLC as the paradigm oncogene-addicted, molecularly-defined lung adenocarcinoma subtype: activating EGFR kinase-domain mutations (dominated by exon 19 deletions and L858R) drive constitutive, ligand-independent signaling through RAS-MAPK, PI3K-AKT-mTOR, and JAK-STAT3, which explains both the initial exquisite sensitivity to EGFR-TKIs and the inevitable emergence of resistance. Falcon is the narrower, pathophysiology/resistance-mechanism-focused report (33 citations), organized around the molecular players, signaling cascades, and on-/off-target resistance catalog. OpenScientist is the broader, more recent 15-domain autonomous report (55 citations) that additionally covers epidemiology, genetic susceptibility, staged treatment algorithms, prognosis, diagnostics, prevention, and model systems. Read together they converge on mechanism while OpenScientist supplies most of the quantitative and clinical-trial breadth.

Agreement

The reports are broadly concordant with no direct contradictions. They agree on the core driver mechanism (constitutive EGFR activation via exon 19 del / L858R feeding the three canonical effector cascades), on osimertinib as the third-generation standard-of-care first-line TKI, and on the resistance landscape being both on-target (C797S after osimertinib) and EGFR-independent (MET/HER2 bypass amplification, oncogenic fusions, and lineage/histologic transformation). They also agree that EGFR-mutant NSCLC has an immunologically cold, immunosuppressive tumor microenvironment (low TMB, impaired antigen presentation, suppressive immune programs) that underlies the poor benefit of single-agent PD-1/PD-L1 blockade, that EGFR mutations are enriched in East Asian and never-smoker adenocarcinoma patients, and that BIM (BCL2L11) loss impairs TKI-induced apoptosis.

Divergence

Divergence is a matter of coverage, recency, and quantitative granularity rather than conflict. OpenScientist uniquely contributes the paradoxical prognostic significance of high PD-L1 (>=50% predicting worse osimertinib outcomes, HR 3.03), quantified brain-metastasis and leptomeningeal burden (25-40% and 3-5%), osimertinib's CNS efficacy and blood-brain-barrier penetration, the detailed pharmacogenomic BIM-deletion story (HR 1.35 for PFS, ~15.8% of Asian patients), GWAS susceptibility loci, and the adjuvant/consolidation trial framing (ADAURA, LAURA) alongside FLAURA. Falcon contributes complementary mechanistic depth on epitranscriptomic (NSUN2-YBX1- QSOX1 m5C) and checkpoint-driven (PD-L1-induced autophagy, PD-L2 upregulation) resistance, and it frames PD-L1 primarily as a resistance mechanism rather than a prognostic marker. The one quantitative discrepancy is the Asian EGFR prevalence band (Falcon ~30-50% vs OpenScientist ~30%), treated as a partial match, not a contradiction.

Integration

The concordant, mechanistically central findings should be promoted into the disorder YAML: the driver-mutation/constitutive-signaling pathophysiology, the ethnic/never-smoker epidemiology, osimertinib as first-line standard of care, the on-target-plus-bypass resistance landscape (C797S, MET/HER2, fusions, transformation), the cold immune microenvironment with limited ICI benefit, and the high CNS/brain-metastasis propensity. These are supported by both providers (or by OpenScientist with quantitative anchoring and Falcon's directional agreement) and map cleanly onto pathophysiology, genetic_factor, epidemiology, treatment, and phenotype sections.

Not integrated (leads)

Several findings are retained as leads pending primary-source verification rather than promoted directly. The paradoxical high-PD-L1 prognosis is a single-provider (OpenScientist) claim whose provider stances differ in kind from Falcon's resistance framing, so it should be verified against its cited trial data before promotion. The pharmacogenomic BIM-deletion effect size and the osimertinib CNS-efficacy/BBB-penetration quantitation are likewise OpenScientist-anchored (Falcon partial or silent) and warrant fetch-reference confirmation of the underlying PMIDs before entering the disorder YAML as quantitative claims.

Cross-provider synthesis comparing falcon (pathophysiology/resistance-focused, 33 citations) and openscientist (comprehensive 15-domain, 55 citations, more recent) reports for EGFR-mutant NSCLC. The two reports are broadly concordant on the core driver mechanism, resistance landscape, cold immune microenvironment, and osimertinib as standard of care; no direct contradictions were found. Divergence is coverage/recency and quantitative granularity: OpenScientist adds the paradoxical high-PD-L1 prognosis, quantitative CNS-metastasis burden, osimertinib CNS efficacy, the pharmacogenomic BIM-deletion detail, and adjuvant/consolidation (ADAURA/LAURA) framing that Falcon omits or states only qualitatively; the two also give slightly different Asian EGFR prevalence bands (~30% vs ~30-50%). best_matching_text values are verbatim excerpts from the cited report files. mondo set to MONDO:0005233 (non-small cell lung carcinoma), the parent entity both providers reference for this molecular subtype.